Phase 1b/2 Study of Combination 177Lu Girentuximab Plus Cabozantinib and Nivolumab in Treatment naïve Patients With Advanced Clear Cell RCC

This study tests a new combination of three cancer treatments — a targeted radioactive drug (177Lu girentuximab), a multi-kinase inhibitor (cabozantinib), and an immunotherapy drug (nivolumab) — in people who have advanced kidney cancer (clear cell renal cell carcinoma) that has not been treated before. **You may be eligible if...** - You are 18 or older - You have been diagnosed with advanced (metastatic or locally advanced) clear cell kidney cancer - You have not received any prior treatment for your kidney cancer - You have at least one measurable tumor on scans - You are in good health (ECOG 0–1) - Your kidney, liver, and blood counts meet the study requirements **You may NOT be eligible if...** - You have received prior treatment for kidney cancer - Your cancer is not clear cell subtype - You are pregnant or breastfeeding - Your organ function does not meet the study's requirements - You are unwilling to use effective contraception during and after the study Talk to your doctor to see if this trial is right for you.